Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 7/20 | 0.46 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.46 |
| ▸ | NCS1 | P62166 | 1/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.44 |
| ▸ | ILK | Q13418 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3642935 | 0.98 | DYRK1A (0.58) | DYRK1AALOX5MEN1KMT2APPARA | |
| SCHEMBL3641501 | 0.86 | PPARA (0.61) | DYRK1APPARAKDM4EMAOB | |
| Lithium Ion SCHEMBL31084584 | 0.84 | DYRK1A (0.56) | DYRK1AALOX5MEN1KMT2APPARA | |
| SCHEMBL3613102 | 0.84 | DYRK1A (0.56) | DYRK1AALOX5MEN1KMT2APPARA | |
| SCHEMBL8400514 | 0.82 | DYRK1A (0.51) | DYRK1AALOX5MEN1KMT2AAKR1B1 | |
| SCHEMBL17161588 | 0.81 | DYRK1A (0.60) | DYRK1AALOX5MEN1KMT2APPARA | |
| SCHEMBL3618193 | 0.78 | MAPT (0.54) | DYRK1AALOX5MEN1KMT2AAKR1B1 | |
| SCHEMBL3642370 | 0.78 | DYRK1A (0.55) | DYRK1AAKR1B1AKR1A1MAOB | |
| SCHEMBL3639457 | 0.77 | PPARA (0.48) | DYRK1APPARA | |
| SCHEMBL3621185 | 0.76 | HDAC6 (0.56) | ALOX5PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| CN-1623537-A | Biaryl sulfonamides and its using method | WYETH CORP (US) | 2005-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | DYRK1A 2885/4885ALOX5 1118/4885MEN1 4000/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | DYRK1A 2885/4885ALOX5 1118/4885MEN1 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.